谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Overall Survival Benefit in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.

Bruce D Cheson,Neil Chua,Jiri Mayer,Greg Dueck,Marek Trněný,Kamal Bouabdallah,Nathan Fowler,Vincent Delwail,Oliver Press,Gilles Salles,John G Gribben,Anne Lennard,Pieternella J Lugtenburg,Günter Fingerle-Rowson,Federico Mattiello,Andrea Knapp,Laurie H Sehn

Journal of clinical oncology official journal of the American Society of Clinical Oncology（2018）

引用 110|浏览67
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要